Despite treatment with maximally tolerated lipid lowering therapy, and LDL-C levels at or below treatment goals, a significant number of patients remain at elevated risk for major cardiovascular events. Thus, there is a need to better understand how other atherogenic lipoproteins are associated with residual CV risk. Although elevated serum TGs have been correlated with increased CV risk, recent evidence suggests that the ability to achieve significant reductions in major CV events from lowering TGs alone may be insufficient.
At the same time, there is compelling evidence that lipoprotein carriers of TGs (i.e. TG-rich remnant lipoproteins, such as VLDL, IDL, and chylomicron remnants) are causally related to the development of CVD and may represent additional markers and/or therapeutic targets for residual CV risk.
In order for clinicians to properly assess and treat residual CV risk related to elevated serum TGs and TG-rich remnant lipoproteins, a more wholistic understanding of the basic science, clinical data, and current treatment landscape is required.
Through this request for proposals, Pfizer seeks to support educational programs focused on understanding residual cardiovascular (CV) risk associated with triglyceride (TG)-rich remnant lipoproteins by:
– Discussing the importance of understanding sources of CV risk beyond LDL-C.
– Discussing relevant basic and clinical science related to TG-rich remnant lipoproteins versus serum TG in atherosclerosis and CV risk.
– Providing context for clinicians to use this information in clinical practice where appropriate.
The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.